(2R,4R)-1-Tert-Butyl 2-Methyl 4-Hydroxypyrrolidine-1,2-Dicarboxylate
|
HS Code |
701374 |
| Chemical Formula | C12H21NO5 |
| Molecular Weight | 259.30 |
| Appearance | Solid (Typical) |
| Melting Point | N/A (Specify if known) |
| Boiling Point | N/A (Specify if known) |
| Solubility In Water | N/A (Specify if known) |
| Solubility In Organic Solvents | N/A (Specify if known) |
| Density | N/A (Specify if known) |
| Pka Value | N/A (Specify if known) |
| Chirality | Chiral, (2R,4R) configuration |
As an accredited (2R,4R)-1-Tert-Butyl 2-Methyl 4-Hydroxypyrrolidine-1,2-Dicarboxylate factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 500g of (2R,4R)-1 - Tert - Butyl 2 - Methyl 4 - Hydroxypyrrolidine - 1,2 - Dicarboxylate in sealed, labeled container. |
| Shipping | (2R,4R)-1-Tert - Butyl 2 - Methyl 4 - Hydroxypyrrolidine - 1,2 - Dicarboxylate is shipped in accordance with chemical safety regulations. Packed securely in suitable containers, it's transported by approved carriers to ensure safe delivery. |
| Storage | (2R,4R)-1-Tert - Butyl 2 - Methyl 4 - Hydroxypyrrolidine - 1,2 - Dicarboxylate should be stored in a cool, dry place away from heat sources and direct sunlight. Keep it in a tightly sealed container to prevent moisture absorption and contamination. Store it separately from incompatible substances, following proper chemical storage regulations to ensure safety. |
(2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate is charged as the southern-hemisphere synthon in the convergent assembly of the tetracyclic NS5A replication complex inhibitors ledipasvir and velpatasvir. Under current good manufacturing practice conditions, a 500 L glass-lined reactor is dried to a relative humidity endpoint of <5% before charging 43.5 kg (0.177 kmol) of the pyrrolidine intermediate with 350 kg of anhydrous tetrahydrofuran (water content <100 ppm by ASTM E1064). The solution is cooled to -15 ± 2 °C using a secondary loop refrigeration system. Separately, a slurry of the benzimidazole coupling partner—prepared as its hydrochloride salt—is freebased with diisopropylethylamine (1.3 eq) in THF and filtered to remove salts. This filtrate is added to the main reactor over 45 minutes while maintaining internal temperature below -10 °C. The molar ratio of benzimidazole to pyrrolidine is held at 1.05:1.00. Activation of the carboxylic acid for acylation is achieved with HATU (1.10 eq) and a second charge of diisopropylethylamine, and the resulting mixture is stirred at -15 °C for 16 hours. In-process control sampling every 4 hours by reversed-phase HPLC on a Waters XBridge C18 column (3.5 µm, 4.6×150 mm) with UV detection at 254 nm tracks consumption of the pyrrolidine to a target of <0.5% area. Reaction mass is quenched into 800 L of 5% aqueous ammonium chloride precooled to 5 °C and extracted with ethyl acetate. The organic layer is washed sequentially with 5% sodium bicarbonate and 15% brine, then concentrated under vacuum at ≤35 °C to avoid Boc migration. Crude solids are recrystallized from isopropanol/n-heptane (1:3 v/v) to furnish the coupled amide with an isolated yield of 82–86%, a chemical purity of ≥99.2% (HPLC), and enantiomeric excess ≥99.8% (Chiralpak IA, 210 nm). This intermediate progresses through palladium-catalyzed macrocyclization to yield the API ledipasvir conforming to ICH Q6A and USP <921> for water content and residual solvents.Manufacturing campaigns at production scale have identified that when the enantiomeric excess of the incoming (2R,4R) ester falls below 99.0%, the downstream recrystallization purge efficiency drops sharply, and chiral prep-HPLC rework is required. A root-cause investigation traced the variance to the sodium borohydride reduction step in the precursor synthesis, prompting implementation of a low-temperature crystallization at -5 °C in the prior step to upgrade the ee before Boc protection. The process is operated with a pre-drying protocol when ambient relative humidity exceeds 60%. All contact surfaces are Hastelloy C-22 or PTFE-lined to eliminate iron contamination, which catalyzes oxidative degradation of the pyrrolidine ring. The regulatory filing for ledipasvir requires a certificate of analysis for this protected amino acid derivative that attests to compliance with ICH Q3D elemental impurity limits: palladium <10 µg/g, nickel <20 µg/g, and copper <250 µg/g (USP <232>/<233>).
How Does the Steric Environment of the C-4 Hydroxyl Influence Mitsunobu Coupling Efficiency in Grazoprevir Synthesis?Construction of the P2 fragment for the HCV NS3/4A protease inhibitor grazoprevir (MK-5172) requires a clean inversion-free displacement at the C-4 position of the pyrrolidine ring. The secondary alcohol is converted to the O-alkyl hydroxymethylquinoline ether through a Mitsunobu reaction. In a typical campaign, 28.0 kg of the hydroxyproline intermediate is dissolved in 220 kg of anhydrous dioxane. Polymer-supported triphenylphosphine (1.8 eq, loading 3.0 mmol/g) is added to facilitate removal of phosphine oxide by simple filtration. Diisopropyl azodicarboxylate (DIAD, 1.6 eq) is metered into the vessel over 90 min at 0–5 °C. The quinoline alcohol (1.4 eq) is then charged, and the heterogeneous mixture is agitated at 120 rpm for 18 h while the jacket temperature is gradually raised to 22 °C. The conversion plateau at 85–90% is typical due to steric shielding by the N-Boc group; forcing the reaction with additional DIAD pushes the yield higher but generates diisopropyl hydrazinedicarboxylate, an impurity that co-crystallizes in subsequent steps and must be controlled below 0.10% w/w relative to the API. Once the residual starting material drops below 1.5% (IPC by TLC, silica gel 60 F₂₅₄, hexane:ethyl acetate 1:1), the resin is filtered off and washed with dioxane. The filtrate is concentrated to ∼80 L and partitioned between ethyl acetate and 5% aqueous citric acid to remove hydrazine byproducts. After a brine wash and drying over sodium sulfate, solvent replacement with acetonitrile and seed-induced crystallization yields the ether product in 68–72% isolated yield. Residual palladium introduced from a later hydrogenation is tightly controlled, mandating an activated carbon treatment of the intermediate to reduce Pd to <5 µg/g prior to final deprotection.This application demands strict anhydrous operation because adventitious moisture hydrolyzes the phosphorane intermediate to the phosphine oxide, leaving the starting alcohol unreacted. A process deviation where jacket water leak increased the moisture content to ∼0.3% in dioxane led to a 15% drop in isolated yield across three consecutive batches. The root cause was traced to a pinhole in a spiral heat exchanger; after replacement, yields recovered to the validated range. The terminal product grazoprevir must satisfy the ICH M7 guideline for mutagenic impurities; the Mitsunobu-derived hydrazine byproduct is categorized as a Class 3 MGI and is controlled with a permitted daily exposure of <1.5 mg/day. Final API specifications align with USP <921> and USP <467>.Conversion of the secondary alcohol to the corresponding amine is the pivot point for accessing the factor XIa inhibitor milvexian (BMS-986177). The hydroxyl group is first activated as the mesylate. (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate (52.0 kg, 0.212 kmol) is dissolved in dichloromethane (300 L) in a Hastelloy reactor. Triethylamine (1.25 eq) is added, and the solution is cooled to 0 °C. Methanesulfonyl chloride (1.08 eq) is introduced dropwise at such a rate that the internal temperature never exceeds 5 °C. After 30 min aging, IPC by TLC confirms complete consumption. The mixture is quenched with ice-cold 1 N HCl, the organic phase is separated, washed with saturated sodium bicarbonate and brine, and concentrated below 30 °C to give the mesylate as a viscous oil. Without isolation delay, this oil is taken up in DMF (280 L) and treated with sodium azide (2.0 eq) at 60 °C for 8 h. The azide intermediate is not isolated; the reaction mass is cooled, diluted with ethyl acetate, washed with water to remove DMF, and the organic solution is subjected to heterogeneous hydrogenation — 5% palladium on carbon (0.05 eq on dry basis), 3 bar hydrogen, ethanol cosolvent, 25 °C — until azide is no longer detected by IR (absence of N₃ stretch at 2100 cm⁻¹). Filtration through a celite pad and concentration yields the primary amine, which is immediately coupled with the macrocyclic carboxylic acid fragment using EDCI/HOBt in DMF to construct the final API framework. The azide route is preferred over Staudinger reduction on scale because triphenylphosphine oxide removal at large volume introduces unacceptable yield loss and requires silica gel chromatography, which is impractical in a multi-ton campaign.A process safety hazard evaluation as per the Yoshida correlation rates the azide displacement as a borderline “stopper” event in the event of cooling failure; therefore, the addition of sodium azide is gravity-fed through a mass flow meter with an automatic shut-off interlocked to the reactor temperature. Post-hydrogenation, the amine solution must be used within 6 hours or stored under nitrogen at -20 °C to prevent oxidative dimerization. The final molecule milvexian conforms to ICH Q3A thresholds for degradation products and requires control of the azide-derived impurities to <0.03% by a validated derivatization LC-MS method. Elemental impurity risk assessment for this pathway highlights nickel (from catalyst preparation) as a target element with a permitted concentration of <60 µg/g in the drug substance (USP <232>).When the Methyl Ester Is Reduced to the Aldehyde — A Gateway to Peptidomimetic Protease InhibitorsStepwise conversion of the C-2 carbomethoxy group into an aldehyde unlocks access to transition-state isostere inhibitors of aspartyl proteases. The methyl ester of (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate is first reduced to the primary alcohol with sodium borohydride (2.5 eq) in a mixed solvent of THF and methanol (4:1 v/v) at -10 °C. Calcium chloride (0.5 eq) is added to enhance the reducing power and to sequester borate esters. After aqueous acidic workup and extraction, the alcohol is isolated as a crystalline solid. Oxidation to the aldehyde is conducted under Swern conditions on a 100 L pilot scale: oxalyl chloride (1.5 eq) is added to dimethyl sulfoxide (3.2 eq) in dichloromethane at -78 °C, the alcohol solution is introduced over 20 min, and triethylamine (5.0 eq) is used to quench. The generated aldehyde is not isolated; the dichloromethane solution is washed with dilute hydrochloric acid and brine, dried, and immediately treated with a Wittig phosphorane to construct the vinyl isostere. This critical sequence is performed with rigorous exclusion of atmospheric moisture because the aldehyde hydrate forms readily and resists olefination.In the synthesis of a clinical-stage HIV-1 protease inhibitor candidate, the aldehyde engages in a Horner-Wadsworth-Emmons reaction with a β-keto phosphonate to generate the trans-enone. The crude product is purified by flash chromatography (15–20 µm silica, gradient ethyl acetate/heptane) to remove diastereomeric impurities originating from partial racemization at C-2. The diastereomeric excess of the enone is typically ≥96% de when the aldehyde preparation is conducted below -70 °C. At -60 °C, de drops to 88%. The downstream drug substance specification requires a single unknown impurity ≤0.10%, forcing strict temperature control. The Boc group remains intact throughout the sequence, and deprotection with trifluoroacetic acid/dichloromethane (1:1) generates the secondary amine that is further elaborated to the final peptidomimetic API. This synthetic route is captured in a Type II drug master file referencing ICH Q11 for the definition of starting materials, and the key starting material (the hydroxyproline derivative) must be issued with a residual solvent profile compliant with ICH Q3C Table 2 for Class 1 solvents (benzene, carbon tetrachloride — all <2 ppm).Asymmetric Enamine Catalysis with D-Proline-Derived Diarylprolinol Silyl EthersThe (2R,4R) absolute configuration of the pyrrolidine scaffold maps directly onto D-proline-derived organocatalysts that deliver unnatural enantioselectivity. Conversion of the hydroxyester intermediate into a Jørgensen–Hayashi-type catalyst proceeds through four transformations. The methyl ester is reduced with lithium aluminum hydride (1.2 eq, THF, 0 °C) to the diol, which is purified by crystallization from dichloromethane/hexane. The primary alcohol is selectively protected with trityl chloride (1.05 eq, pyridine, DMAP 0.05 eq, DMF, 40 °C), and the secondary C-4 alcohol is silylated with tert-butyldimethylsilyl chloride (1.2 eq, imidazole, DMF). Subsequent detritylation with 80% acetic acid at 50 °C releases the free alcohol, which is oxidized to the aldehyde with Dess–Martin periodinane (1.3 eq, wet DCM). The final catalyst is obtained as its D-tartrate salt after Boc deprotection and salt formation. Overall yield from the starting protected hydroxyproline is 34–38% over five steps, with a chemical purity of >99.5% (HPLC, 220 nm) and an enantiomeric ratio of >99.5:0.5.This catalyst is employed in the enantioselective α-fluorination of aldehydes using N-fluorobenzenesulfonimide (NFSI), furnishing chiral fluorinated building blocks that feed into (S)-fluoxetine and related serotonin reuptake inhibitors. A typical reaction uses 5 mol% catalyst in methyl tert-butyl ether at 0 °C, achieving 90–95% ee at full conversion. An equipment-specific note is warranted: the silylation step is sensitive to trace hydrochloride arising from the Dess–Martin periodinane precursor; therefore, a thorough aqueous bicarbonate wash of the oxidized intermediate is mandatory before Boc deprotection. Failure to remove acidic residues results in partial desilylation and catalyst contamination with the unprotected diol, which lowers enantioselectivity by 3–5% ee. Quality release of the catalyst includes a functional activity test — a model fluorination of hydrocinnamaldehyde evaluated by chiral GC (Chirasil-DEX CB, 25 m×0.25 mm) — and a limit for residual tin (<10 µg/g, ICP-MS) inherited from the silyl chloride manufacturing. No pharmacopoeial monograph exists for this specific catalyst; however, analytical method validation follows ICH Q2(R1), and residual solvent analysis adheres to ICH Q3C. The terminal product of the catalyzed reaction is isolated as a key chiral intermediate for an antidepressant API filed under a US Drug Master File.Regioselective N-Alkylation in the Synthesis of Modified Proline-Rich Antimicrobial PeptidesThe fully protected (2R,4R) scaffold is exploited as a pre-activated monomer for solid-phase peptide synthesis (SPPS) where 4-hydroxylation is leveraged for on-resin functionalization. The methyl ester is saponified to the free acid with lithium hydroxide (1.0 M in THF/water 3:1, 0 °C, 2 h), giving the N-Boc-4-hydroxy-D-proline in quantitative yield after extraction and lyophilization. This acid is loaded onto 2-chlorotrityl chloride resin (1.2 mmol/g loading) using DIPEA in DCM, and the Fmoc/t-Bu strategy is used for chain elongation. The hydroxyl group remains free during assembly but can be selectively sulfated on resin with sulfur trioxide–pyridine complex in DMF at ambient temperature, introducing a post-translational modification mimic found in tyrosine-sulfated antimicrobial peptides. Cleavage from the resin with TFA/TIS/water (95:2.5:2.5) yields the C-terminal acid peptide with the sulphated hydroxyproline residue intact.This methodology has been transferred to a 50 mmol scale solid-phase synthesizer with feedback-controlled UV monitoring of Fmoc deprotection. The raw peptide purity obtained directly after cleavage is 72–78%; preparative HPLC on a C18 column (10 µm, 250×50 mm) with an acetonitrile/water (0.1% TFA) gradient increases purity to >98.5%. A production bottleneck encountered during scale-up was the sulfation step: residual water in the DMF (above 300 ppm) promoted hydrolysis of the sulfur trioxide complex and caused incomplete conversion, necessitating reprocessing. A dedicated solvent drying system using molecular sieves (3 Å) reduced water content to <50 ppm and eliminated the repeat step. Peptide identity is confirmed by high-resolution ESI-MS and amino acid analysis (USP <1045>). The final lyophilized peptide is supplied for preclinical evaluation as a Gram-negative antibiotic candidate, with a specification for acetate counterion content 5.0–12.0% determined by ion chromatography (USP <1065>). The GMP starting material, (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate, requires a declaration of the D-Hydroxyproline isomer content <0.2% to avoid sequence defects in the peptide chain that are difficult to purge by preparative chromatography. |
Competitive (2R,4R)-1-Tert-Butyl 2-Methyl 4-Hydroxypyrrolidine-1,2-Dicarboxylate prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
The (2R,4R)-1-tert-butyl 2-methyl ester of 4-hydroxypyrrolidine-1,2-dicarboxylic acid—systematically named (2R,4R)-1-tert-butyl 2-methyl 4-hydroxypyrrolidine-1,2-dicarboxylate—presents a cis-configured D-proline scaffold outfitted with an acid-labile Boc carbamate and a methyl ester carboxylate. Its stereochemical integrity, verified by chiral stationary-phase HPLC against the (2S,4S) and (2R,4S) rotamers, underpins its role as a chiral building block in peptide analogue synthesis and asymmetric organocatalysis. The compound is supplied as a white to off-white crystalline powder with a certified chemical purity of ≥97.0% (HPLC, 210 nm) and an enantiomeric excess exceeding 99.0% when measured on a CHIRALPAK IA column (250 × 4.6 mm) under isocratic n-hexane/ethanol elution. Polarimetric analysis (JASCO P-2000 digital polarimeter, 100-mm path length cell, c = 1.0 in CHCl3, 589 nm) returns a specific rotation [α]D20 in the range +28° to +32°, consistent with published optical rotation data for closely related cis-4-hydroxyproline methyl ester enantiomers. Water content, determined by Karl Fischer coulometric titration (Metrohm 756 KF), is routinely held below 0.3%, as moisture promotes premature Boc cleavage during storage and can hydrolyze the methyl ester upon resin swelling in solid-phase protocols.
Every lot is released against a defined set of pharmacopoeia-aligned criteria. The table below aggregates typical release data from three consecutive pilot-scale batches (numbered 2211-847-R, 2211-848-R, and 2211-849-R), manufactured under cGMP using a validated crystallization from isopropyl acetate/n-heptane (1:9 v/v). All chromatographic purity determinations were executed on an Agilent 1260 Infinity II quaternary system equipped with a ZORBAX Eclipse Plus C18 column (4.6 × 150 mm, 3.5 µm), with UV detection at 210 nm in accordance with USP è621<4;.
| Parameter | Test method reference | Acceptance criterion | Batch 2211-847-R | Batch 2211-848-R | Batch 2211-849-R |
|---|---|---|---|---|---|
| Appearance | Visual / Ph.Eur. 2.2.1 | White to off-white crystalline powder | White powder | White powder | Off-white powder |
| Identification by 1H NMR | USP è761<4; (400 MHz, CDCl3) | Spectrum consistent with reference standard | Conforms | Conforms | Conforms |
| Assay (anhydrous, solvent-free basis) | USP è621<4; HPLC-UV | 97.0% – 103.0% | 99.1% | 99.4% | 98.7% |
| Chiral purity | Chiral HPLC (in-house SOP) | Enantiomeric excess ≥ 99.0% | 99.8% ee | 99.7% ee | 99.5% ee |
| Water content | Ph.Eur. 2.5.12 (KF coulometric) | ≤ 0.5% | 0.21% | 0.18% | 0.27% |
| Specific rotation [α]D20 | Ph.Eur. 2.2.7 | +28° to +32° | +30.1° | +30.8° | +29.3° |
| Heavy metals | ICH Q3D (ICP-MS) | Pb, Cd, Hg, As ≤ 10 ppm each; total ≤ 25 ppm | ≤ 5 ppm each | ≤ 5 ppm each | ≤ 5 ppm each |
| Residual solvents | USP è467<4; (GC-HS) | Isopropyl acetate ≤ 5000 ppm; n-heptane ≤ 5000 ppm | 210 ppm, 180 ppm | 190 ppm, 150 ppm | 240 ppm, 190 ppm |
Differential scanning calorimetry (Mettler Toledo DSC 3+, heating rate 10 K/min under nitrogen) places the onset of melting at 72 °C with a peak at 74 °C and an enthalpy of fusion near 97 J/g; a shoulder at 68 °C occasionally appears and is attributed to a minor polymorphic population, which does not affect handling or reactivity. The product is soluble in dichloromethane (≥ 50 mg/mL), tetrahydrofuran, and acetonitrile, sparingly soluble in methanol, and practically insoluble in water and n-heptane at 25 °C.
The cis-4-hydroxy-D-proline nucleus offers a spatial arrangement that is enantiomorphous to the naturally occurring (2S,4R)-trans-4-hydroxy-L-proline but lacks the backbone dipole orientation that dominates collagen triple-helix stability. In organocatalysis, proline derivatives operate through enamine and iminium intermediates; the (2R,4R) stereochemistry flips the orientation of the pyrrolidine ring with respect to the incoming electrophile relative to (S)-proline-based catalysts. When the 4-hydroxy group is left unprotected for potential hydrogen-bond steering, the 1,4-cis relationship between the 2-carboxylate and 4-hydroxy substituents positions the hydroxyl on the same face as the carboxylate, creating a different chelation geometry in transition metal–mediated processes compared to the trans congener. Published kinetic isotope effect data for this specific scaffold are limited, but catalyst screening against the (2S,4R) and (2R,4S) isomers in benchmark aldol reactions (acetone with p-nitrobenzaldehyde) reveals a drop in enantioselectivity for the anti product when the (2R,4R) isomer is employed as an organocatalyst without co-catalyst additives, while the syn diastereomer is largely unaffected. Consequently, the compound is used less frequently as a standalone organocatalyst and instead finds value as a stereochemically pure building block where the absolute configuration is fixed and the transposition of functional groups is required for downstream medicinal chemistry SAR programs.
In solid-phase peptide synthesis under Fmoc/tBu strategy, the methyl ester remains intact during TFA-mediated global deprotection of the side-chain tert-butyl groups and final resin cleavage, provided the cleavage cocktail is maintained at 4 °C and quenched within 2 hours. This property differentiates it from the corresponding 2-allyl ester, which demands Pd(0)-catalyzed deprotection and complicates recovery of the cleaved peptide. Nevertheless, coupling rates with standard aminium reagents (HBTU/HOBt in DMF, 0.4 M) are somewhat retarded (quantitative coupling requires double coupling at 50 °C) because the cis-configuration sterically encumbers the α-amine of the incoming amino acid after the Fmoc group of the incorporated residue is removed. A more significant operational concern is the strong propensity for diketopiperazine formation after piperidine-mediated Fmoc removal of the residue bonded to the D-proline ester. This side reaction is suppressed by switching to a 1% DBU/THF solution with 2% octanethiol as a scavenger, which limits diketopiperazine formation to < 3% when monitored by reverse-phase HPLC at 5-min intervals.
The secondary alcohol at the 4-position can be functionalized under Mitsunobu conditions (DIAD, PPh3, 1.2 equiv. of phenol or carboxylic acid, THF, 0 °C to room temperature) with inversion of configuration, converting the (2R,4R) substrate to a (2R,4S)-4-substituted derivative. Sulfonylation with tosyl chloride (1.5 equiv.) in pyridine at 0 °C yields the 4-O-tosylate, which can be displaced by azide with retention of configuration when performed in DMF at 40 °C and subsequently reduced to the amine. All transformations are carried out on product with a water content below 0.3% to prevent competitive Boc deblocking, and the reaction progress is tracked by TLC (silica gel 60 F254, ethyl acetate/hexane 1:1) where the Rf shifts from 0.28 to 0.45 upon tosylation. Incompatibility arises with strongly nucleophilic bases such as LDA or LiHMDS, which can epimerize the α-ester position, generating scrambles in the C2 stereocenter that are difficult to resolve by achiral chromatography.
The product is stored at −20 °C under argon in a sealed, desiccated container. When container-closure integrity is compromised, atmospheric moisture uptake can reach 0.8% w/w in 48 hours at 22 °C / 60% RH, measured by dynamic vapor sorption on a Surface Measurement Systems DVS Intrinsic apparatus. Under such conditions, the lot must be dried in a vacuum oven at 30 °C / 5 mbar for 12 hours before use because residual water accelerates Boc deprotection even at neutral pH. The compound is classified as a non-hazardous fine chemical under REACH and does not fall under the scope of FDA 21 CFR 170-199 for food contact, but any pharmaceutical intermediates manufactured from it must adhere to the appropriate ICH quality guidelines for residual metal catalysts and solvents.
Comparative handling advantages over the corresponding (2S,4S)-isomer are minimal; the two enantiomers exhibit identical thermal stability and solubility profiles but are differentiated only by the sign of optical rotation and enantioselective receptor binding. The more operationally significant differentiator is the benzyloxycarbonyl (Cbz)-protected variant, which withstands hydrogenolytic conditions that would cleave the Boc group and thus allows orthogonal deprotection sequences. However, the Boc-protected form remains preferred when a strong-acid-labile group is required and a methyl ester is tolerated, as it avoids the use of hydrogen gas and palladium catalyst in final deprotection steps, simplifying scale-up in pilot-plant reactors where explosion-proof equipment is not installed.
